Articles

Poll

Podcasts

Slideshows

Videos

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Robert Giugliano, MD, breaks down his prespecified subanalysis of the VESALIUS-CV trial, evaluating evolocumab’s effect on cardiovascular mortality.

Evolocumab Improves Survival in Patients Without Prior MI or Stroke

Jose Nicolau, MD, PhD, discusses the results of his subanalysis of the VESALIUS-CV trial, examining secondary rather than first MACE.

Evolocumab Prevents Recurrent Cardiovascular Events Following MI or Stroke

Catch up on any stroke-related news you may have missed during 4 action-packed days of presentations and trial readouts at ESC 2026.

ESC 2026 Stroke Spotlight Recap: 5 Practice-Changing Trials to Know

Charalambos Antoniades, MD, PhD, discusses the recent trial investigating an AI-powered stroke and atrial fibrillation predictor.

ORFAN-MAESTRIA: AI Predicts Cardioembolic Stroke, Atrial Fibrillation from CT Scans

Ashkan Shoamanesh, MD, discusses individualizing stroke prevention after ENRICH-AF, from LAAO to factor XI inhibitors to the ASPIRE trial.

Beyond Edoxaban: Rethinking Stroke Prevention, With Ashkan Shoamanesh, MD

Ashkan Shoamanesh, MD, explains ENRICH-AF's mixed stroke and bleeding results, and a dosing signal that may point to a safer approach.

ENRICH-AF: A Dosing Clue Emerges After Edoxaban's Miss, With Ashkan Shoamanesh, MD

A roundup of the top cardiology news out of ESC Congress2026 on day 2, spanning primary prevention, novel therapies, and antibiotic stewardship.

ESC Congress 2026: Day 2 Recap—6 Headlines to Know

Philippe Gabriel Steg, MD, discusses the full results of the terminated trial, reflecting on their impact on the ongoing LIBREXIA-AF and LIBREXIA-Stroke trials.

LIBREXIA ACS Fails to Improve Cardiovascular Outcomes, Doesn’t Increase Bleeding Risk

Milvexian added to standard antiplatelet therapy did not lower MACE or increase intracranial/fatal bleeding versus placebo after ACS.

LIBREXIA ACS: Milvexian Fails to Reduce MACE after Acute Coronary Syndrome 

The ENRICH-AF trial found edoxaban did not significantly reduce stroke or systemic embolism but increased major bleeding in patients with AF and prior intracranial hemorrhage.

ENRICH-AF: Edoxaban Increases Bleeding Without Reducing Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.